⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408354 | 0.76 | — | — | |
| SCHEMBL566552 | 0.76 | — | — | |
| SCHEMBL8215521 | 0.73 | — | — | |
| SCHEMBL8215520 | 0.73 | — | — | |
| SCHEMBL15513419 | 0.72 | — | — | |
| SCHEMBL4858511 | 0.70 | — | — | |
| SCHEMBL3906946 | 0.70 | — | — | |
| SCHEMBL4066794 | 0.70 | — | — | |
| SCHEMBL4274065 | 0.70 | — | — | |
| SCHEMBL303510 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390303-A1 | CANCER TREATMENT BY COMBINATION OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-07 | — | — | US | disclosed |
| EP-4245301-A1 | CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO Pharmaceutical Co., Ltd. (JP) | 2023-09-20 | — | — | EP | disclosed |
| US-20220048881-A1 | TRICYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-17 | — | — | US | disclosed |
| US-11192876-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-07 | — | — | US | disclosed |
| EP-3482760-B1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-11065226-B2 | Combination comprising EP4 antagonist and immune checkpoint inhibitor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| CN-109475520-B | Combinations comprising an EP4 antagonist and an immune checkpoint inhibitor | 小野药品工业株式会社 | 2021-05-14 | — | — | CN | disclosed |
| EP-3778562-A1 | TRICYCLIC SPIRO COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-111039916-A | Tricyclic spiro compounds | 小野药品工业株式会社 | 2020-04-21 | — | — | CN | disclosed |
| US-20200102284-A1 | TRICYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-04-02 | — | — | US | disclosed |
| US-20190255013-A1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| EP-3482760-A1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | Ono Pharmaceutical Co., Ltd. (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-20180319764-A1 | TRICYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-08 | — | — | US | disclosed |
| US-10077247-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-09-18 | — | — | US | disclosed |
| US-20180002308-A1 | TRICYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3243813-A1 | TRICYCLIC SPIRO COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2017-11-15 | — | — | EP | disclosed |
| EP-2444401-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8569504-B2 | Imidazopyridine compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2444401-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |